Latest Commercial Strategy News

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.

Blue Star Helium has successfully started helium production at its Pinon Canyon plant, marking a key milestone as it prepares for commercial sales and expansion in 2026.

Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.

Lunnon Metals has secured critical mining proposal approval for its Lady Herial gold deposit, moving the project closer to production under a binding ore purchase deal with St Ives Gold Mining.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.

Skin Elements Limited has completed a $2.5 million placement to fund the commercial rollout of its ECO Nurture bio-stimulant, targeting sustainable kiwifruit orchard protection in New Zealand.

Atomic Eagle Limited announces Phil Hoskins as new CEO following Daniel Major's unexpected non-start, spotlighting the Muntanga Uranium Project's substantial resource base.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.